Delisting HCV-infected Liver Transplant Candidates Who Improved After Viral Eradication

Outcome 2 Years After Delisting

Giovanni Perricone; Christophe Duvoux; Marina Berenguer; Paolo A. Cortesi; Carmen Vinaixa; Rita Facchetti; Chiara Mazzarelli; Susanne-Rasoul Rockenschaub; Silvia Martini; Cristina Morelli; Sara Monico; Riccardo Volpes; Georges-Philippe Pageaux; Stefano Fagiuoli; Luca S. Belli; for the European Liver and Intestine Transplant Association (ELITA)


Liver International. 2018;38(12):2170-2177. 

In This Article


A large number of HCV-infected patients with decompensated cirrhosis (DC) on the waiting list for liver transplantation (LT) have been recently treated with second-generation DAAs. As a result of this, almost 25% of them could be delisted because of clinical improvement.[1–3] This is similar to what previously occurred in hepatitis B virus (HBV) liver transplant candidates who were treated with nucleos/tide (NUC), where one-third were subsequently delisted because of clinical improvement, with the great majority remaining stable for a long period.[4] Whether such a favourable long-term outcome can also be achieved after DAA therapy is an important and still unanswered issue. Our previous ELITA study[1] showed that 1 in 4 patients could be delisted; however, because of short follow-up, the long-term risk of de novo decompensation and HCC development after delisting could not be assessed. This present study addresses possible clinical complications post-delisting after a median follow-up of almost 2 years.